Jeppe Christensen-Romme
Glostrup, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 42 publications
Residual inflammation in the cerebrospinal fluid after short- and long-term natalizumab treatment in relapsing-remitting multiple sclerosis.
Journal: Frontiers in immunology
Published: February 25, 2026
Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study.
Journal: Journal of neurology, neurosurgery, and psychiatry
Published: January 13, 2026
Repetitive transcranial magnetic stimulation to alleviate fatigue in multiple sclerosis-study protocol for a randomized sham-controlled double-blinded clinical trial.
Journal: Frontiers in neurology
Published: December 03, 2025
Are exercise booster sessions effective at preserving exercise-induced effects in people with multiple sclerosis? A randomised controlled trial: results from the MSBOOST trial.
Journal: Journal of science and medicine in sport
Published: August 28, 2025
Corrigendum to "Cerebrospinal fluid soluble CD27 is associated with CD8+ T cells, B cells and biomarkers of B cell activity in relapsing-remitting multiple sclerosis" [Journal of neuroimmunology vol. 381 (2023): 578128].
Journal: Journal of neuroimmunology
Published: April 11, 2025
Profiling the Cerebrospinal Fluid Proteome in Progressive Multiple Sclerosis: Treatment Effects and Associations with IgM Oligoclonal Bands.
Journal: Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology
Published: April 10, 2025
Chitinase-1 in cerebrospinal fluid and white matter injury in patients with progressive multiple sclerosis.
Journal: Journal of neuroimmunology
Published: December 03, 2024
Profiling of B cells and their subsets by whole blood gene expression analysis versus flow cytometry in multiple sclerosis.
Journal: Multiple sclerosis and related disorders
Published: July 11, 2024
Association of Cortical Lesions With Regional Glutamate, GABA, N-Acetylaspartate, and Myoinositol Levels in Patients With Multiple Sclerosis.
Journal: Neurology
Published: June 13, 2024
Extended interval dosing with ocrelizumab in multiple sclerosis.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: April 22, 2024
Neoehrlichiosis associated with ocrelizumab in a patient with multiple sclerosis: A case report.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: March 01, 2024
Effects of anti-CD20 therapy on circulating and intrathecal follicular helper T cell subsets in multiple sclerosis.
Journal: Clinical immunology (Orlando, Fla.)
Published: February 28, 2024
Last Updated: 09/26/2026